Trial Profile

An Open-Label Phase 1/2 Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etentamig (Primary)
Indications Amyloid light-chain amyloidosis
Focus Adverse reactions
Sponsors AbbVie

Most Recent Events

17 Dec 2025 Planned End Date changed from 1 Feb 2028 to 1 Sep 2031.
17 Dec 2025 Planned primary completion date changed from 1 Oct 2026 to 1 Sep 2031.
02 Dec 2025 According to a Abbvie media release, data from this trial will be presented at the 2025 American Society of Hematology (ASH) Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com